PCI 3.06.26

Current Edition

Current Features

Subsection - Neurodegenerative Diseases

From Depression to Deep-Learning: Leveraging iPSC and AI Platforms for Evidence-Based Depression Treatment

Continue reading

Subsection - Oncology

Essential DMPK Strategies for IND Success

Continue reading

Subsection - Cell and Gene Therapy

When the Gene Editing Guide is the Drug

Continue reading

Upcoming Events

AI in Drug Discovery
Auto Draft
Auto Draft
Elrig
Auto Draft
CPHI
DDL 2026
Biotechnology Show 13.02.26

Advertisement

Advertisement

A&M Stabtest April 26

Advertisement

Biopharma Group – 19th March 2025

Advertisement

Micron View

Advertisement

Bachem skyscraper

Alcami Strengthens Commercial Operations with Appointment of Will Isom as Vice President of Laboratory Services Sales

Alcami, a leading contract development and manufacturing organisation (CDMO), today announced the appointment of biologics industry veteran Will Isom as Vice President of Laboratory Services Sales. The creation of this role marks an important step in strengthening Alcami’s commercial organisation and expanding support for clients across its growing biologics portfolio.

In his new role, Mr. Isom will lead Alcami’s commercial strategy for laboratory services, deepen engagement with biotechnology and pharmaceutical partners, and support the continued expansion of Alcami’s standalone analytical offerings. 

His appointment reflects Alcami’s ongoing commitment in delivering reliable solutions for clients increasingly complex biologic therapies.

“Will brings a rare combination of scientific understanding, commercial leadership, and operational experience,” said Katie Schlipp, President, Laboratory Services. “His expertise will help strengthen client partnerships and accelerate growth across our analytical services and biologics business.”

Mr. Isom brings more than two decades of experience in biologics development, quality control, commercial strategy and operational leadership. His career includes leadership roles at Charles River Laboratories, where he advanced through multiple commercial and business development positions and later served as Site Director following the acquisition of Cognate BioServices. Most recently, he led Texcell’s global commercial organisation, overseeing commercial strategy for advanced therapy programmes.

With Mr. Isom’s leadership, Alcami continues to enhance its commercial capabilities and reinforce its position as a trusted partner for biologics development, analytical testing and manufacturing.

Advertisement

Richter: Wed 23 October 2024, 09:03

Advertisement

Aseptic Tech

Advertisement

Steribar – 12.05.2025

Advertisement

PharmExcel

Advertisement

Polypure hompage

Advertisement

Gen Xpro

Advertisement

Alphinity

Advertisement

Crown Bioscience

Advertisement

Shimadzu

Advertisement

CPC